Additional Contribution to the Liquidity Agreement with Natixis

        Print
| Source: DBV Technologies

BAGNEUX, France, March 31, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced an additional contribution on March 31st, 2014 of 300,000 euros to the liquidity agreement held by Natixis in accordance with the Charter of Ethics established by the AMAFI of March 8, 2011 and approved by the Autorité des Marchés Financiers.

As a reminder, as of December 31st, 2013, the following elements were in the liquidity account:
- 5,253 DBV Technologies shares
- €263,429.63

For information, the following elements appeared on the liquidity account at the time of the implementation of the liquidity contract:
-  0 DBV Technologies share
-   €300,000.00

About DBV Technologies:

DBV Technologies is opening up a decisive new approach to the treatment of allergy - a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy - a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

CAUTION: Viaskin® is not approved for sale in the USA.

DBV Technologies Contacts

David Schilansky          Nathalie Donne
Chief Financial Officer          Director Business Development & Corporate Communications
Tel. : +33(0)1 55 42 78 75                          Tel. : +33(0)1 55 42 78 72
david.schilansky@dbv-technologies.com                        nathalie.donne@dbv-technologies.com       
DBV IR and Media Contacts

Alan S. Roemer

U.S. Investor Relations

The Trout Group

Tel. : +1 646 378-2945

aroemer@troutgroup.com
BMC Communications

Media Relations

Brad Miles

Tel. : +1 646-513-3125

brad@bmccommunications.com
 

Additional Contribution to the Liquidity Agreement with Natixis http://hugin.info/156437/R/1773074/604156.pdf

HUG#1773074